hybrid drugs of the invention provide a unique delivery of an antibiotic and a nsaid for the treatment of ophthalmic bacterial infections and for the prevention of inflammation a single drug entity is advantageous to individual dosing of each drug because of the ability for simultaneous dosing and elimination of washout concerns when applying each drug separately the use of an antibiotic nsaid hybrid drug is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye the anti inflammatory component of the composition is useful in treating inflammation associated with physical trauma to ophthalmic tissues inflammation associated with bacterial infections and inflammation resulting from surgical procedures the combination of an antibiotic and nsaid is also useful in post operative inflammation where there is an increased chance of bacterial infection the composition of the invention may also be used prophylactically in connection with various ophthalmic surgical procedures that create a risk of bacterial infection other examples of ophthalmic conditions which may be treated with the compositions of the present invention include infective conditions associated with inflammation and where the use of nsaid is acceptable such conditions may include but are not limited to conjunctivitis keratitis blepharitis endophthalmitis red eye dacyrocystitis hordeolum corneal ulcers anterior blepharitis posterior blepharitis meibomian gland dysfunction dry eye disease keratocojunctivitis sicca ocular pain ocular pain and inflammation post ocular surgery bacterial conjunctivitis anterior uveitis post surgical inflammation inflammatory conditions of the palpebral and bulbar conjunctiva cornea.